June is ALS Awareness Month — a time to reflect, unite, and push forward with renewed purpose. For me, it’s a moment to look back on how far we’ve come in ALS research, and to look ahead with hope for what’s still possible
I’ve been involved in ALS research for the past 14 years. When I started in this field, my research focused on the ALS-linked protein SOD1. At that time, we were trying to understand how its misfolding and aggregation contributed to the disease. Fast forward to 2025, Health Canada approved Qalsody (tofersen), the first therapy in Canada for people with ALS who carry a pathogenic SOD1 variant.
To have started my career studying that very protein, and to now see a therapy targeting its underlying biology, is a powerful reminder of what long-term, sustained research can achieve.
Today, I serve as the Director of Canadian Research at ALS Canada. I work alongside researchers, clinicians, people living with ALS, and their caregivers — my everyday inspirations. After eight years at ALS Canada, I’ve seen firsthand how carefully funding decisions are made and how donor support translates into meaningful change.
That’s why I give. I donate to ALS Canada because I believe in our commitment to funding high-quality research and supporting people affected by ALS.
